Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
about
Bioengineering Models for Breast Cancer ResearchMolecular and clinical implementations of ovarian cancer mouse avatar modelsCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicineTechnologies for deriving primary tumor cells for use in personalized cancer therapyPatient-derived xenograft models of breast cancer and their predictive powerCurrent status and evolution of preclinical drug development models of epithelial ovarian cancerInfluence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenograftsInherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involvedProstate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cellsEfficient and simple approach to in vitro culture of primary epithelial cancer cellsThe Merkel cell polyomavirus minor capsid proteinInference and validation of predictive gene networks from biomedical literature and gene expression data.Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.How Consistent are Publicly Reported Cytotoxicity Data? Large-Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements.Optimization of cell lines as tumour models by integrating multi-omics data.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsPre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.Individual patient oesophageal cancer 3D models for tailored treatment.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.The RPTEC/TERT1 cell line models key renal cell responses to the environmental toxicants, benzo[a]pyrene and cadmiumPatient-derived xenograft models: an emerging platform for translational cancer researchEntry tropism of BK and Merkel cell polyomaviruses in cell cultureU-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells.Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems.Assessment of cancer cell line representativeness using microarrays for Merkel cell carcinomaPrediction of resistance to chemotherapy in ovarian cancer: a systematic review.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesMolecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid.Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell LinesCancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Targeting of Rac GTPases blocks the spread of intact human breast cancer.Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.Recurrent oral cancer: current and emerging therapeutic approaches.
P2860
Q26770495-724FF905-2598-42C4-A1A7-18AB912D7142Q26786724-55C5D820-5851-4AC4-9BE2-132B6DB7243EQ26800337-DBA2DECA-1F0D-42B0-8609-C0345638D1EBQ26829581-6B617D0D-72D5-40FD-A3AA-180E338A0484Q27026531-878C324C-F61F-40F6-8FB2-5D4CCE109051Q27028117-3B707C0A-1403-418A-BCF4-32D37B70D359Q27321370-5212386C-B4D7-46DF-A5CA-2707659B73D9Q28486233-8CD9F23B-C625-4A6F-B2C2-C2469F5D725AQ28533786-75514509-63C6-4D74-B7AF-9BBF857FCE48Q28539620-488391DA-93D9-4269-9341-7FC4E4DE5091Q28588419-4394D5EA-5109-4873-AAE8-4B7F95C16BA5Q28681646-9C973218-D299-43D4-84C7-FA3B080FC631Q30791224-34252FDC-336D-4ED3-9C0B-5583A3FCE909Q30841262-75A178F7-4675-4EAC-B0C4-5FE216E86C60Q31018677-9AE10592-B9F7-49CB-ABC3-2E1EB7EE4DB0Q31134293-56FB0343-4F23-4B1B-9225-57AB1FF131B7Q33555287-4F18D83E-566D-473D-9E66-C29AB8F1A1FCQ33626025-A7130F1E-5B86-4332-BC4A-AE3D866F34C7Q33641924-E01C946C-F5BC-4F46-B09F-7DF7855A30E6Q33648440-B79EE11D-9ABB-4453-B449-5C60E29E7E1DQ33763765-E61E1012-2568-46E1-9E55-80E4B6960DA4Q33894635-79E08CAC-5FC2-419C-BA58-C5F7A22ADFD6Q34025933-EC9CB005-5A17-4F6B-A9E1-8726D062669FQ34205518-7C54541E-BB78-4AE8-ACAE-B159B0976D4FQ34364604-3DC16D14-0FD1-47C0-8C00-F4C423B6CA90Q35000404-7F160CBF-E720-4DBF-B549-C6416496B69DQ35101229-3AFDC829-1AD5-43B2-9BD8-91550539ECAAQ35196335-2211196F-CD91-4806-801B-362DD4261322Q35212386-F94C1C2D-EF93-4EFD-8088-48735627B2A7Q35602135-22990E23-B03E-4A4E-BF6F-028FED2EC8F9Q35618225-C98D1574-2E5C-421E-B500-0E358CA09584Q35817482-99EAB49D-1DF9-428F-8630-1F93B090FB9AQ35909089-4A15309B-87B0-49F6-A0B2-AA5D9E5169A2Q35974087-A45F6E6C-F98B-4D53-8BF1-A404AF39EA87Q36037500-029BC3FA-8B85-4306-BD3B-C4DD02404C7EQ36094989-6EACD404-D1D0-496F-AB4E-01AF95D9C5E5Q36105474-13306E8E-7868-4B5A-A66A-962F8230B5B0Q36234042-4058A0B6-1199-4B59-872C-E730508E1557Q36266655-44842B33-CE41-4C8A-A497-C0E8793CBAB5Q36283038-106675B2-C961-43B8-B236-FAF23319ADC5
P2860
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Redefining the relevance of es ...... l anti-cancer drug resistance.
@ast
Redefining the relevance of es ...... l anti-cancer drug resistance.
@en
type
label
Redefining the relevance of es ...... l anti-cancer drug resistance.
@ast
Redefining the relevance of es ...... l anti-cancer drug resistance.
@en
prefLabel
Redefining the relevance of es ...... l anti-cancer drug resistance.
@ast
Redefining the relevance of es ...... l anti-cancer drug resistance.
@en
P2093
P2860
P356
P1476
Redefining the relevance of es ...... l anti-cancer drug resistance.
@en
P2093
Anil K Sood
Ben Davidson
Bo R Rueda
Chirayu Patel
Jean-Pierre Gillet
Josiah N Orina
Lisa J Green
Meena I Vora
Michael M Gottesman
Miguel Marino
P2860
P304
18708-18713
P356
10.1073/PNAS.1111840108
P407
P577
2011-11-08T00:00:00Z